



RLL-258US

1681  
TAW

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MEHTA et al.

Serial No.: 10/523,208

Filing Date: 9/1/2005

Group Art Unit: TBA

Title: 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES  
USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS

CERTIFICATE OF MAILING

I certify that the following correspondence:

- Transmittal of Information Disclosure Statement
- Information Disclosure Citation (Supplemental)
- Copy of cited reference
- Postcard

is being deposited on April 6, 2006 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Dolci  
Susan Dolci

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-258US

In Re Application Of: MEHTA et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/523,208	9/1/2005	TBA	026815	TBA	

Title: 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-258US

In Re Application of: MEHTA et al.

APR 11 2006  
PATENT & TRADEMARK OFFICE

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/523,208	9/1/2005	TBA	026815	TBA	

Title: 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature of Person Mailing Correspondence

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.


William D. Hare  
Signature

Dated: April 5, 2006

William D. Hare  
Reg. No. 44,739  
Ranbaxy Inc.  
600 College Road East, Suite 2100  
Princeton, NJ 08540  
Tel. (609) 720-5378  
Fax (609) 514-9779

cc:

# INFORMATION DISCLOSURE CITATION



SUPPLEMENTAL

Docket No.: RLL-258US

Serial No.: 10/523,208

Applicants: SILAMKOTI *et al.*

Filed: 1/27/2005

Group:

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

S1 C1	Dobson and Raphael, "729. The synthesis of DL-baikiaiin", <i>Journal of the Chemical Society</i> , 3642-3647 (1958)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.